RxSight

What RxSight does

RxSight is a publicly traded ophthalmic medical device company (NASDAQ: RXST) headquartered in Aliso Viejo, California, that develops and commercializes the Light Adjustable Lens (LAL) system — the first and only FDA-approved intraocular lens whose power can be customized after cataract surgery. The platform consists of a photosensitive silicone IOL (available in LAL and enhanced LAL+ variants), a Light Delivery Device (LDD) that emits controlled UV light to reshape the implanted lens post-operatively, a proprietary inserter, and UV-protective eyewear required during the adjustment phase. Surgeons use the system to fine-tune lens prescription based on actual healing measurements rather than pre-surgical estimates, achieving 92% of eyes within 0.50 D of target manifest refraction and approximately 2x the rate of 20/20 uncorrected vision versus monofocal IOLs.

The business model is a two-part razor-and-blade hardware sale: the LDD is sold as capital equipment to surgical centers (1,134 units installed through 2025), and the LAL is sold as a high-margin consumable for each cataract procedure (28,611 units in Q4 2025 alone). LAL is positioned as a premium IOL with out-of-pocket patient cost not covered by standard Medicare, distributed through direct enterprise sales to ophthalmic surgeons with a complementary patient-pull motion via a Find a Physician locator and content marketing. Full-year 2025 revenue was $134.5M, with LAL representing 86% of Q4 sales and LDD revenue declining 48% as the installed base matured.

RxSight serves both cataract surgeons (B2B enterprise customers) and adult cataract surgery patients (B2C end users), particularly those with pre-existing corneal astigmatism of 0.75 D or more. The company has expanded internationally into Canada, the UK, Germany, Spain, France, Hong Kong, Singapore, and South Korea, and holds 11 granted U.S. patents across LAL, LDD, and inserter technology. Founded in 2015 (formerly Calhoun Vision), the company went public and has raised approximately $165M through post-IPO offerings since 2023 to fund commercial expansion, holding $228.1M in cash at year-end 2025.

Name

RxSight

Legal name

RxSight, Inc.

Website

https://rxsight.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

251–500 employees

Short description

RxSight is a publicly traded ophthalmic medical device company that developed the first FDA-approved adjustable intraocular lens, enabling post-surgical vision customization via UV-light treatment, serving cataract surgeons and patients globally.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics) (HLAHAJAH)

akta.pro secondary industry

Cornea, External Disease & Refractive Surgery (LASIK/PRK) (HLAKAKAF)

Keywords

• Ophthalmic medical devices
• Intraocular lens technology
• Cataract surgery solutions
• Premium IOL implants
• Post-surgical vision adjustment

Headquarters

HQ city

Aliso Viejo

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Light Adjustable Lens (LAL) Sales: Primary revenue driver. LAL revenue grew 12% year-over-year and accounted for a record 86% of total company sales in Q4 2025. Revenue generated from lens implants sold to surgeons/hospitals for use in cataract procedures.
2. Light Delivery Device (LDD) System Sales: Capital equipment sales of the Light Delivery Device to surgical centers. LDD revenue declined 48% in 2025 versus prior year. Placements of 163 LDD units during 2025 brought installed base to 1,134 units.
3. UV-Protective Glasses: Accessories provided post-surgery including tinted, clear, and clear reader glasses. Part of the treatment protocol requiring patients to wear UV-protective eyewear during adjustment phase.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

RxSight develops, manufactures, and commercializes the Light Adjustable Lens (LAL) system, the first and only FDA-approved adjustable intraocular lens for cataract surgery. The LAL is made of proprietary photosensitive material that can be non-invasively customized post-operatively using the Light Delivery Device (LDD), which delivers controlled UV light beams to fine-tune lens power and correct residual astigmatism based on actual healing outcomes. Supporting offerings include the LAL+ enhanced lens, the surgical Inserter, and UV-protective eyewear required during the adjustment phase.

Product overview

RxSight is an ophthalmic medical technology company that has commercialized the world's first and only adjustable intraocular lens system for cataract surgery. The product portfolio consists of the Light Adjustable Lens (LAL) and Light Adjustable Lens+ (LAL+), which are implanted during cataract surgery and then customized post-operatively using the Light Delivery Device (LDD) to deliver UV light treatments that reshape the lens based on actual healing outcomes. The system also includes an Inserter for surgical implantation and UV-protective glasses required during the adjustment phase. Unlike fixed IOLs that must be determined pre-surgery, the LAL system allows surgeons to fine-tune prescription after the eye heals, enabling correction of residual astigmatism and optimization of visual outcomes.

Differentiator

Problem solved

Functional benefit

Brands

• Light Adjustable Lens™ (LAL®): The first and only FDA-approved intraocular lens that can be customized after cataract surgery using UV light treatments.
• Light Delivery Device™ (LDD™)

Products and services

• Light Adjustable Lens (LAL) FDA-approved intraocular lens made of photosensitive material that can be customized after cataract surgery using UV light treatments from the Light Delivery Device, allowing surgeons to fine-tune vision based on actual post-healing outcomes. Implanted by cataract surgeons in adult patients undergoing premium IOL procedures.
• Light Adjustable Lens+ (LAL+) Enhanced version of the Light Adjustable Lens with improved features for post-surgical vision customization after cataract surgery. Targets cataract surgeons and premium IOL patients seeking advanced adjustable lens outcomes.
• Light Delivery Device (LDD) Non-invasive system that delivers controlled UV light beams to precisely reshape the Light Adjustable Lens after cataract surgery, enabling post-operative customization of lens power and correction. Sold as capital equipment to cataract surgeons and ambulatory surgical centers.
• Inserter Surgical instrument used by cataract surgeons to implant the Light Adjustable Lens during cataract surgery.
• RxSight UV-Protective Glasses UV-protective eyewear required during the adjustment phase after LAL implantation to shield the photosensitive lens from unintended UV exposure until the prescription is locked in. Available in tinted, clear, and clear reader (+1.50 and +2.50 add) options for post-operative cataract patients.

Quantifiable outcome

• 92% of eyes achieved results within 0.50 D of target manifest refraction spherical equivalent (MRSE)
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• American College of Eye Technicians (ACET)minorStrategic or Co-development PartnerRxSight participates as a subsidized partner in ACET's 8-week virtual training program for ophthalmic technicians. The program addresses workforce shortages in ophthalmology. RxSight's involvement is one of several pharmaceutical and medical device company sponsors including Alcon, Bausch + Lomb, Dompe, EyePoint Pharmaceuticals, and Topcon Healthcare.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Alcon: Alcon is the global leader in ophthalmic surgery, offering the PanOptix premium trifocal IOL that directly competes with RxSight's LAL in the premium cataract surgery channel. Alcon also manufactures the LenSx femtosecond laser system that RxSight's CEO co-founded, making it both a customer-adjacent incumbent and a potential acquirer profile.
• Carl Zeiss Meditec: Carl Zeiss Meditec manufactures IOLs (CT LUCIA, CT SPHERIS) along with surgical microscopes and ophthalmic diagnostic equipment used in cataract surgery. The company competes with RxSight across both the IOL and surgical equipment categories and has global scale.

Direct peers

• Johnson & Johnson Vision (TECNIS): J&J Vision's TECNIS portfolio includes premium IOLs (TECNIS Symfony, TECNIS Synergy, TECNIS PureSee) that compete head-to-head with RxSight's LAL in the U.S. premium cataract channel. Both companies target the same ophthalmic surgeons and cataract patients seeking spectacle independence.
• Bausch + Lomb: Bausch + Lomb offers premium IOLs (enVista, Crystalens, Trulign) directly competing with RxSight's LAL. The company is a broad incumbent in ophthalmic surgical devices and also has a partnership with ACET for ophthalmic technician training alongside RxSight.
• HOYA Surgical Optics: HOYA Surgical Optics is a global manufacturer of premium intraocular lenses (Vivinex, iSert) that competes directly with RxSight in the cataract surgery IOL market, particularly in international markets where RxSight is expanding.

Emerging players

• STAAR Surgical: STAAR Surgical manufactures Implantable Collamer Lenses (ICL/EVO) for refractive surgery, addressing the broader vision correction market that overlaps with RxSight's premium positioning. While focused on phakic IOLs rather than cataract IOLs, STAAR competes for premium vision-correction patients and surgeon mindshare.
• Glaukos Corporation: Glaukos is a medical device company focused on ophthalmic interventional therapies (MIGS devices for glaucoma). While not a direct IOL competitor, Glaukos shares RxSight's profile as a U.S.-based public ophthalmic medical device innovator targeting specialty surgeons and procedural expansion.
• EyePoint Pharmaceuticals: EyePoint Pharmaceuticals is a specialty ophthalmic company developing sustained-release drug delivery for eye diseases. It overlaps with RxSight in ophthalmic clinical channels and partners alongside RxSight in ACET training programs, representing an adjacent ophthalmic MedTech peer.
• Lensar: Lensar manufactures the ALLY robotic laser cataract surgery system, competing in the premium cataract surgery equipment space adjacent to RxSight's LDD. Both companies target premium-IOL adopting ophthalmic surgeons and share conference presence at ASCRS and AAO.

Others

• Topcon Healthcare: Topcon Healthcare provides ophthalmic diagnostic and surgical equipment used in cataract surgery workflows. While not a direct IOL competitor, Topcon is a co-sponsor with RxSight in the ACET ophthalmic technician training program and shares the ophthalmic surgical ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCE4pQ_QLTldOeowCmf39D6w
• Facebookfacebook.com/rxsight
• LinkedInlinkedin.com/company/calhoun-vision-inc-
• Instagraminstagram.com/rxsight
• Xx.com/RxSight

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds10 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RxSight